The trusted partner. For better lives.
Who we are
We develop and manufacture medicines, ensuring a safe supply of life-improving products. This is done by our 200 proficient employees at our four sites in Norway. Curida is on a growth journey where revenue and growth is expected to continue in the coming years, as a series of products is currently being added to the Curida portfolio through technology transfer and product development projects.
In Curida, we live by our core values. We are:
1. Introduction
Corporate ethics are about how we behave towards each other and the world around us. The Code of Conduct (CoC) is the foundation of our corporate culture and defines the core principles and ethical standards by which we create value in our company. The CoC gives guidelines to how we shall behave both internally and externally. CoC shall stimulate ethical awareness and be a guideline for everyday actions.
The CoC applies to all member of the board, all employees and representatives of Curida. Curida aims for these guidelines also to be well known by customers, suppliers, acquired companies and partners. All managers are responsible for the CoC being known, lived up to, and that actions will be taken if codes are broken. Each employee has a responsibility to read and follow the CoC.
Violation of the CoC will be subjected to disciplinary action including possible termination as well as potential criminal prosecution. To ensure that every part of our value chain fulfils Curida’s high standards of quality and ethical conduct, we routinely perform controls on compliance with the principles described in this document.
2. Values, personal conduct, working environment and human rights
In Curida, we live by our core values. These values guide our behaviour and our decisions – internally and externally.
Curida expects employees who live by our values, who treat others with respect and maintain an open communication. In Curida there shall be no discrimination or harassment of age, gender, disabilities, race, sexual orientation, ethnic origin, religion or political affiliation. Curida shall be an engaging workplace with an inclusive working environment. Curida expects that no employees make any actions that could harm the Curida brand.
When we are working in other cultures than our own, we treat everyone – persons as well as organisations – with respect, and we are acting in accordance with national laws and regulations. We also pay attention to local etiquette and values in the countries we are working in. In meetings with contacts outside Curida we appear as professionals in behaviour and conduct. Curida supports and respects internationally proclaimed human rights, including those specified by the International Labour Organization. The company respects the right to freedom of association and opposes any form of child labour, forced labour or discrimination, and requests all representatives and suppliers to follow the same principles.
Curida undertakes development services and manufacturing of pharmaceutical products. We therefore operate in a highly regulated business, where premium quality on products and processes are of the highest importance.
3. Sustainability
We manage our environmental impact and seek to continuously improve the sustainability of our activities by. We work to increase efficiency of the use of renewable energy in our facility, economizing on our use of non-renewable energy and raw materials; minimizing the amount of waste we generate, and minimizing any adverse environmental effects associated with the manufacturing of products in our portfolio.
Curida strictly complies with all environmental, health, and safety laws that apply to our operations, but we also strive to go beyond legal minimums to proactively reduce the potential for environmental impact of our activities. We aim to work with partners who also regard minimal environmental impact of their value chain as an increased quality in the end product, namely a safe and effective pharmaceutical product or medical device.
4. Conflicts of interests
No personal interests or personal gain shall affect your work in Curida. As an employee you shall never take actions or have interests that make it difficult to perform your work objectively and effectively. You shall never be a part of, or influence decisions or actions, where you can be a part of a conflict of interest between you and the company. In such situations Curida is expecting openness and loyalty to Curida.
Curida employees shall not hold positions or carry out work for other companies without permission from a superior. Engagements in external duties and positions shall not affect your working relationship with Curida. Each employee is responsible to inform Curida management about a real or potential conflict of interest.
Curida was established when a group of employees and management acquired the Takeda manufacturing site in Elverum, Norway in 2015. The acquisition followed Takeda’s decision to shut the site down and move all manufacturing to other parts of Europe. The manufacturing site, which has existed since 1974, had been part of Nycomed until 2011.
Under Takeda, the Elverum site had around 200 employees and was the largest private employer of the area. Curida started out with a smaller operation at its inception in 2015. Since then, the site has experienced significant growth in terms of both revenue and employment, and it will in the near future approach the size it saw at its historic peak in 2013.
The employees showed great courage when starting their own company under uncertain conditions in 2014 and 2015. Before Norwegian Prime Minister Erna Solberg reopened the Elverum site under the Curida name on July 1st 2015, the employees had put more than 10,000 hours of volunteer work into making the new company a reality.
The employees and management remained the only owners of Curida until December 2017, when Norwegian family offices Canica and Klaveness Marine invested in Curida. Shortly after, the Norwegian governmental investment fund Investinor and family office Stokke Industri followed. The employees and management still control more than 20 percent of the shares in Curida.
In 2018, to increase the Norwegian footprint, Curida acquired Ås Produksjonslab, located south of Oslo. Ås Produksjonslab performs fill and finish of bottle products for the Norwegian pharmacy market.
The growth continues, and in 2022 Curida acquired Diatec Monoclonals, a biologics company in Oslo. With this Curida is entering the biologics market and is as such positionned for further growth.
People
Ole J. Dahlberg brings 25 years of experience from the life science industry. In addition to co-founded three start-up companies, Dahlberg worked both on the commercial side, and in R&D leadership roles, for German Biotech company Qiagen. Over the past 15 years Dahlberg has been in executive leadership roles in Life Technologies, as Managing Director for Norway based Dynal Biotech, and later for Thermo Fisher Scientific.
Until 2021 Dahlberg was based in California, USA, working as Vice President & General Manager with responsibility for Thermo Fisher Scientific’s Cell Biology Division. Dahlberg holds a few biotech company board positions, and currently works as Independent Executive in the life science industry. Mr. Dahlberg holds a Master of Science in Genetics and Marine Biology from University of Oslo.
From May 1st, 2024, Anders Larsson is employed as the CEO of Curida. Anders has been acting COO in Curida since fall 2023 and have a deep knowledge of Curida business and operations.
Anders brings extensive experience from the pharma, pharmacy and pharma services industry from his role as CEO in Norway for Boots pharmacy and Alliance Healthcare pharma wholesale (Cencora). Furthermore, Anders has over a decade of experience in development and end-to-end operations in FMCG, food and beverage from multiple executive roles in Orkla and Carlsberg, located in Scandinavia and also in Asia. Educationally, Anders holds a MSc in Chemical Engineering from Chalmers University Gothenburg and Imperial College London, as well as a BSc in finance from Gothenburg University.
Terje Gabrielsen has been Chief Financial Officer of Curida since September 2017. Prior to his appointment in Curida, he worked as CFO Thales Norway, Denofa, Nammo Group, Raufoss Group, Unitor North America and Alcatel Telettra. Mr Gabrielsen holds an MSc in Business Administration from BI Norwegian Business School.
Jens Schanche Dølør possesses a comprehensive background in military education and experience, having held various leadership and human resources roles across different levels within the armed forces. Additionally, he has garnered HR expertise from the healthcare sector. Since March 2024, Jens has served as the Head of Human Resources at Curida Group. In this capacity, he and his HR team deliver a full spectrum of HR support to all organizational levels.
Stefan Einarsson joined Curida in April 2024, bringing over 20 years of experience in the life sciences industry. He has held various sales and marketing roles at companies such as GlaxoSmithKline, Mylan and Sandoz. In recent years, he has been in the Contract Development and Manufacturing Organization (CDMO) sector, working as Business Development Manager at APL, Director of Market Development at Recipharm, and Business Development Director at Ardena. Mr. Einarsson holds a BSc in Business Administration and an engineering degree from the University of Växjö.
Peter Sjølie holds a M.Sc. in Production Technology from NTNU Trondheim. Since graduating Peter has worked in the Norwegian research organization SINTEF and space and defence group NAMMO. Starting as a project manager responsible for tech transfers (TT) in Curida in 2019 Peter has obtained extensive experience in the pharmaceutical industry. Especially through leading Curida’s single largest TT-project transferring 15 products (200+ SKU’s) over the course of two years. Since Q4 2021 Peter has been responsible for all tech transfer and development projects in Curida Small Molecules.
Ørjan Leiknes Apeland holds an MScPharm degree from the University of Oslo, obtained in 2016. Since graduating, he has accumulated extensive experience in the pharmaceutical industry, focusing on quality control and manufacturing. Mr. Apeland commenced his role with the Curida Group in 2020 and currently holds overall responsibility for Ås Produksjonslab AS. He also has the overall responsibility for sustainability in the group.
Mira has a M.Sc in Molecular Bioscience and Immunology and joined the Diatec team in 2018. After 3 years as Key Account Manager she moved on to fill the position as Site Manager at our Diagnostics production site. When the company was aquired by Curida Biologics in 2022, Curida Diatec reorganized and Mira was asked to temporary lead operations at the two manufacturing sites in addition to business development. In May 2024 Mira was promoted to Director of Curida Diatec. Mira has a background from Basal Medical Research at Oslo University Hospital and a broad experience in sales and customer service from other industries.
Contact
Want to partner with us?
Contact us to learn more about our pharmaceutical development or manufacturing solutions. We look forward to discussing your next project with you! Our customers range from academic research, start-ups and early stage Biotech companies, to Big Pharma.
Curida Elverum
Solbærvegen 5
2409 Elverum
Norway
+47 62 42 83 00
post@curida.no
Director, Ås produksjonslab
Ørjan L. Apeland
orjan.apeland@aasproduksjonslab.no
Customer service, raw materials
Mette Stenstad
mette.stenstad@curida.no
Ås Produksjonslab
Gamleveien 2
1434 Ås
Norway
post@aasproduksjonslab.no
This website uses cookies